Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy

Stanford Health Care

The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.

The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes. Journal of diabetes science and technology Mader, J. K., Wong, J. C., Freckmann, G., Garcia-Tirado, J., Hirsch, I. B., Johnson, S. B., Kerr, D., Kim, S. H., Lal, R., Montaser, E., O'Donnell, H., Pleus, S., Shah, V. N., Ayers, A. T., Ho, C. N., Biester, T., Dovc, K., Farrokhi, F., Fleming, A., Gillard, P., Heinemann, L., López-Díez, R., Maahs, D. M., Mathieu, C., Quandt, Z., Rami-Merhar, B., Wolf, W., Klonoff, D. C. 2025: 19322968251333441

Abstract

This consensus report evaluates the potential role of continuous glucose monitoring (CGM) in screening for stage 2 type 1 diabetes (T1D). CGM offers a minimally invasive alternative to venous blood testing for detecting dysglycemia, facilitating early identification of at-risk individuals for confirmatory blood testing. A panel of experts reviewed current evidence and addressed key questions regarding CGM's diagnostic accuracy and screening protocols. They concluded that while CGM cannot yet replace blood-based diagnostics, it holds promise as a screening tool that could lead to earlier, more effective intervention. Metrics such as time above range >140 mg/dL could indicate progression risk, and artificial intelligence (AI)-based modeling may enhance predictive capabilities. Further research is needed to establish CGM-based diagnostic criteria and refine screening strategies to improve T1D detection and intervention.

View details for DOI 10.1177/19322968251333441

View details for PubMedID 40444471